Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-04 22:30 |
Monthly information on share capital and company voting rights
|
English | 90.9 KB | ||
| 2024-11-05 22:30 |
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid …
|
English | 126.8 KB | ||
| 2024-11-05 22:30 |
Cellectis présente de multiples stratégies pour améliorer l'efficacité des cell…
|
French | 156.5 KB | ||
| 2024-10-30 21:30 |
Cellectis publiera ses résultats financiers du troisième trimestre 2024 le 4 no…
|
French | 132.8 KB | ||
| 2024-10-30 21:30 |
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
|
English | 154.8 KB | ||
| 2024-10-22 08:00 |
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at th…
|
English | 67.7 KB | ||
| 2024-10-22 08:00 |
Cellectis présentera des données sur des TALE Base Editors ainsi que sur son pr…
|
French | 78.1 KB | ||
| 2024-10-02 22:30 |
Monthly information on share capital and company voting rights
|
English | 90.8 KB | ||
| 2024-10-02 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 120.9 KB | ||
| 2024-09-04 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 80.3 KB | ||
| 2024-09-04 22:30 |
Monthly information on share capital and company voting rights
|
English | 71.7 KB | ||
| 2024-09-03 22:30 |
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Ne…
|
English | 77.8 KB | ||
| 2024-09-03 22:30 |
Cellectis présente des preuves précliniques de l’efficacité des cellules CAR T …
|
French | 57.2 KB | ||
| 2024-08-26 22:30 |
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Appr…
|
English | 64.0 KB | ||
| 2024-08-26 22:30 |
Cellectis publie un article dans Molecular Therapy sur la conception de cellule…
|
French | 75.2 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
